|
Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme. |
| |
|
Travel, Accommodations, Expenses - Roche/Genentech |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Kristian Lindstroem Jensen |
No Relationships to Disclose |
| |
|
|
|
Research Funding - Agilent |
Patents, Royalties, Other Intellectual Property - Agilent |
| |
|
Employment - Agilent; DAKO |
Patents, Royalties, Other Intellectual Property - XSpray Microparticles AB |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Bjarne Winther Kristensen |
Research Funding - Agilent |
Patents, Royalties, Other Intellectual Property - DAKO |